Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity;Un traitement par exenatide pendant six mois augmente le produit hyperbolique HOMA essentiellement par une amélioration de la fonction B

Diabetes and Metabolism

Volumn 36, Issue 4, 2010, Pages 293-298

  Preumont, V ^a   Hermans, M P ^a   Brichard, S ^a   Buysschaert, M ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

cell function; Exenatide; Glycaemic control; Hyperbolic product; Insulin resistance

Indexed keywords

ADIPONECTIN; EXENDIN 4; HEMOGLOBIN A1C; HYPERGLYCEMIC AGENT; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; SULFONYLUREA;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DIABETIC PATIENT; DIAGNOSTIC VALUE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; GASTRIC INTOLERABILITY; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PROSPECTIVE STUDY; RISK FACTOR; SLEEP APNEA SYNDROME; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PEPTIDES; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VENOMS;

EID: 77958591734     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2010.02.001     Document Type: Article

References (29)

1. Kahn S.E. The relative contributions of insulin resistance and ß-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003, 46:3-19.
2. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformine-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1090-1100.
3. Kendall D.M., Riddle M.C., Rosenstock J., Zhuang D., Kim D.D., Fineman M.S., et al. Effects of exenatide (exendin-4) on glycemic control over 30weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083-1091.
4. Heine R., Van Gaal L.F., Johns D., Mihm M.J., Widel M.H., Brodows R.G. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143:559-569.
5. Klonoff D.C., Buse J.B., Nielsen L.L., Guan X., Bawlus C.L., Holcombe J.H., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3years. Curr Med Res 2008, 24:275-286.
6. Bunck M.C., Diamant M., Cornér A., Eliasson B., Malloy J.L., Shaginian R., et al. One-year treatment with exenatide improves ß-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients. Diabetes Care 2009, 32:762-768.
7. Hermans M.P., Levy J., Morris R.J., Turner R.C. Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia 1999, 42:678-687.
8. Hermans M.P., Levy J., Morris R.J., Turner R.C. Comparisons of tests of ß-cell function across a range of glucose tolerance from normal to diabetes. Diabetes 1999, 48:1779-1786.
9. Preumont V., Hermans M.P., Lebecque P., Buysschaert M. Glucose homeostasis and genotype- phenotype interplay in cystic fibrosis patients with CFTR gene ΔF508 mutation. Diabetes Care 2007, 30:1187-1192.
10. Munoko T.N., Hermans M.P. Phenotypic characterization of first generation Maghrebian migrants with type 2 diabetes: a gender-based comparison with a reference North-Caucasian Belgian cohort. Diabetes Metab Syndr Clin Res Rev 2008, 2:115-124.
11. Kahn S.E., Prigeon R.L., Mc Culloch D.K., Boyko E.J., Berman R., Schwartz M.W., et al. Quantification of the relationship between insulin sensitivity and ß-cell function in human subjects: evidence for a hyperbolic function. Diabetes 1993, 42:1663-1672.
12. Zander M., Madsbad S., Madsen J.L., Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and ß-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359:824-830.
13. Fehse F., Trautmann M., Holst J.J., Halseth A.E., Nanayakkara N., Nielsen L.L., et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocr Metab 2005, 90:5991-5997.
14. Buse J.B., Klonoff D.C., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data form the open-label, uncontrolled extension of three double-blind, placebo controlled trials. Clin Ther 2007, 29:139-153.
15. Moretto T.J., Milton D.R., Ridge T.D., Macconell L.A., Okerson T., Wolka A.M., et al. Efficacy and tolerability of exenatide monotherapy over 24weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008, 30:1448-1460.
16. Mari A., Nielsen L.L., Nanayakkara N., DeFronzo R.A., Ferrannini E., Halseth A. Mathematical modeling shows exenatide improved ß-cell function in patients with type 2 diabetes treated with metformin of metformin and a sulfonylurea. Horm Metab Res 2006, 38:838-844.
17. Vilsboll T., Brock B., Perrild H., Levin K., Lervang H., Kolendorf K., et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic ß-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med 2008, 25:152-156.
18. Marre M., Shaw J., Brändle M., Bebakar W.M., Kamaruddin N.A., Strand J., et al. Liraglutide, a once daily human GLP-1 analogue, added to a sulphonylurea over 26weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009, 26:268-278.
19. Nauck M., Frid A., Hermansen K., Shah N., Tankova T., Mitha I., et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes (The LEAD (liraglutide effect and action in diabetes) - 2 study. Diabetes Care 2009, 32:84-90.
20. Yki-Jarvinen H. Glucose toxicity. Endocr Rev 1992, 13:415-431.
21. Drucker D.J. The biology of incretin hormones. Cell Metab 2006, 3:153-165.
22. Oriot P., Feys J.-L., Mertens de Wilmars S., Misson A., Ayache L., Fagnart O., et al. Insulin sensitivity, adjusted ß-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month retrospective study. Diabete Metab 2008, 34:490-496.
23. Christiansen T., Paulsen S.K., Bruun J.M., Ploug T., Pedersen S.B., Richelsen B. Diet-induced weight loss and exercise alone and in combination enhance the expression of adiponectin receptors in adipose tissue and skeletal muscle, but only diet-induced weight loss enhanced circulating adiponectin. J Clin Endocrinol Metab 2010, 95.
24. Yang W.S., Lee W.J., Funahashi T., Tanaka S., Matsuzawa Y., Chao C.L., et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001, 86:3815-3819.
25. Vella A., Shah P., Basu R., Basu A., Holst J.J., Rizza R.A. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes 2000, 45:611-617.
26. Young A., Gedulin B., Bhavsar S., Bodkin N., Jodka C., Hansen B., et al. Glucose-lowering and insulin-sensitizing actions of exenidin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mubatta). Diabetes 1999, 48:1026-1034.
27. Gedulin B., Nikoulina S., Smith P., Gedulin G., Nielsen L., Baron A., et al. Exenatide (exendin-4) improves insulin sensitivity and ß-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005, 146:2069-2076.
28. Buse J.B., Rosenstock J., Sesti J., Schmidt W.E., Montanya E., Brett J.H., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47.
29. Blonde L., Klein E.J., Han J., Zhang B., Mac S.M., Poon T.H., et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006, 8:436-447.